Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Obedience

Obedience

According to obedience research, we may harm others under the forceful pressures of an authority figure (Milgram, 1974). How about if the inappropriate orders were delivered with less force? The increasing interdependence between nurses and physicians compelled Hofling and his colleagues to explore nurses’ reactions to a potentially harmful medical request made by the perceived authority figure, the doctor (Hofling, Brotzman, Dalrymple, Graves, & Pierce, 1966). In this situation,...

Ethics in Research

Ethics in Research

Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Deuruxolitinib: New Approval.

Clinical drug investigation·2026

Same author

Remibrutinib: First Approval.

Drugs·2026

Same author

Correction: Ifupinostat: First Approval.

Drugs·2026

Same author

Ifupinostat: First Approval.

Drugs·2025

Same author

Fosrolapitant/Palonosetron: First Approval.

Drugs·2025

Same author

Nipocalimab: First Approval.

Drugs·2025

Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026

Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026

Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026

Same journal

Relacorilant: First Approval.

Drugs·2026

Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026

Same journal

Linerixibat: First Approval.

Drugs·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 13, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

Bevifibatide: First Approval.

¹Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

|February 12, 2026

Summary

This summary is machine-generated.

Bevifibatide, a glycoprotein IIb/IIIa antagonist, is now approved in China for acute coronary syndrome patients undergoing percutaneous coronary intervention. This treatment aims to reduce risks like stent thrombosis and slow blood flow.

More Related Videos

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

Related Experiment Videos

Last Updated: Feb 13, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

Area of Science:

Cardiovascular Pharmacology
Integrin Receptor Antagonism

Background:

Bevifibatide is a cyclic heptapeptide antagonist targeting glycoprotein IIb/IIIa and αvβ3 integrin receptors.
It was developed by Bio-Thera Solutions for acute coronary syndrome (ACS) management.

Purpose of the Study:

To summarize the development milestones of bevifibatide leading to its regulatory approval.
To highlight bevifibatide's role in reducing complications following percutaneous coronary intervention (PCI).

Main Methods:

Review of bevifibatide's development pathway.
Analysis of its mechanism of action as a GP IIb/IIIa antagonist.

Main Results:

Bevifibatide received approval in China on June 25, 2024.
Approved for ACS patients requiring PCI to mitigate risks such as acute occlusion, stent thrombosis, no reflow, and slow blood flow.
First approval is as an adjunct therapy alongside PCI, antiplatelet, and anticoagulant treatments.

Conclusions:

Bevifibatide's approval marks a significant advancement in ACS treatment.
It offers a new therapeutic option to improve outcomes in patients undergoing PCI.
The drug's efficacy in reducing thrombotic complications is a key benefit.